Mission Wealth Management LP Increases Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Mission Wealth Management LP increased its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 253.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,081 shares of the medical instruments supplier's stock after purchasing an additional 2,926 shares during the quarter. Mission Wealth Management LP's holdings in Becton, Dickinson and Company were worth $935,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Brighton Jones LLC grew its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 877 shares during the period. Foster Victor Wealth Advisors LLC bought a new position in Becton, Dickinson and Company during the 1st quarter valued at about $6,406,000. Assenagon Asset Management S.A. grew its holdings in Becton, Dickinson and Company by 1.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 8,047 shares of the medical instruments supplier's stock valued at $1,843,000 after purchasing an additional 79 shares during the last quarter. Van ECK Associates Corp increased its position in shares of Becton, Dickinson and Company by 3.1% during the fourth quarter. Van ECK Associates Corp now owns 14,738 shares of the medical instruments supplier's stock worth $3,344,000 after acquiring an additional 450 shares during the period. Finally, Proficio Capital Partners LLC purchased a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $21,607,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president now directly owns 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Stock Up 0.3%

Shares of NYSE BDX traded up $0.58 during midday trading on Friday, reaching $169.17. The company's stock had a trading volume of 1,265,720 shares, compared to its average volume of 1,991,883. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The stock has a 50 day simple moving average of $180.23 and a 200-day simple moving average of $211.63. The stock has a market capitalization of $48.49 billion, a price-to-earnings ratio of 32.27, a PEG ratio of 1.27 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping the consensus estimate of $3.28 by $0.07. The firm had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business's quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.17 earnings per share. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.46%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is presently 79.39%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on BDX shares. Wells Fargo & Company downgraded shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. Morgan Stanley cut their target price on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Stifel Nicolaus cut their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Finally, Piper Sandler cut shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and cut their price target for the stock from $260.00 to $185.00 in a report on Friday, May 2nd. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $219.22.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.